OTCMKTS:MYCOF Mydecine Innovations Group (MYCOF) Stock Price, News & Analysis $0.0059 0.00 (-20.27%) As of 11:37 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Mydecine Innovations Group Stock (OTCMKTS:MYCOF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MYCOF alerts:Sign Up Key Stats Today's Range$0.0059▼$0.005950-Day Range N/A52-Week Range$0.0007▼$0.0115Volume771 shsAverage Volume7,589 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Read More Receive MYCOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mydecine Innovations Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYCOF Stock News HeadlinesMydecine Innovations Group Delays Financial Filings Amid Audit ProgressJune 12, 2025 | tipranks.comMydecine Innovations Group Inc - Delisting From AQSEMarch 21, 2025 | uk.finance.yahoo.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 29 at 2:00 AM | Brownstone Research (Ad)Mydecine Innovations Group Inc (MYCOF)December 18, 2024 | uk.investing.comMydecine Innovations Group Inc - Mydecine Announces Filing of Q3 Financial StatementsNovember 22, 2024 | finanznachrichten.deMydecine Innovations Group Inc - Suspension of TradingOctober 10, 2024 | finanznachrichten.deMydecine Innovations Group Inc. (MYCOF)September 21, 2024 | finance.yahoo.comMydecine Innovations Group Inc - Mydecine Provides Bl-Weekly Status ReportMay 17, 2024 | finanznachrichten.deSee More Headlines MYCOF Stock Analysis - Frequently Asked Questions How have MYCOF shares performed this year? Mydecine Innovations Group's stock was trading at $0.0028 at the beginning of 2025. Since then, MYCOF stock has increased by 110.7% and is now trading at $0.0059. How were Mydecine Innovations Group's earnings last quarter? Mydecine Innovations Group Inc. (OTCMKTS:MYCOF) posted its quarterly earnings results on Tuesday, November, 16th. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.50. When did Mydecine Innovations Group's stock split? Shares of Mydecine Innovations Group reverse split on Thursday, April 21st 2022.The 1-50 reverse split was announced on Thursday, April 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Mydecine Innovations Group? Shares of MYCOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/16/2021Today8/29/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryCandy & Soda Current SymbolOTCMKTS:MYCOF CIKN/A Webwww.mydecine.com Phone(604) 687-2038FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:MYCOF) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mydecine Innovations Group Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mydecine Innovations Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.